Boston University School of Medicine (BUSM) and the Amyloidosis Research Consortium (ARC) have partnered to provide an on-demand program where attendees will learn about amyloidosis care. This program is open to all specialties, but is primarily targeted to practicing physicians and nurses that most commonly see and treat amyloidosis patients.
This program will address the following gaps:
- Clinicians need to better understand the presentation of amyloidosis symptoms and how to identify and diagnose possible amyloidosis patients.
- Clinicians need to know what steps to take once they have identified a possible amyloidosis patient and who, how and when to refer.
- Clinicians need to have current knowledge of treatments and the impact on progression of disease and survival.
- Clinicians need to understand the important role of multidisciplinary teams in caring for patients with amyloidosis.
Led by an internationally renowned faculty team of amyloidosis experts, this program spotlights various aspects of the diagnosis, treatment and long-term management of amyloidosis. Attending clinicians will learn skills to identify, correctly diagnose, and treat amyloidosis patients in their clinical practice, as well as when and how to refer to specialty centers. The attendees will also learn about the value of multidisciplinary teams, and how to build an amyloidosis program to best support patients.
This program was recorded at a virtual meeting in April 2021. For ease of viewing, it has been split into four parts that can be taken independently.
The Amyloidosis Research Consortium (ARC) is a global organization founded in 2015 accelerating the development of and access to new and innovative treatments for amyloidosis. ARC brings together experts in the field to address the challenges that exist in developing diagnostic tools and carrying out collaborative and innovative clinical trials. To reach its mission, ARC invests in a strategic portfolio of research designed to make a significant contribution to the curability of systemic amyloidosis in the shortest time possible. ARC is the only patient-driven organization exclusively focused on amyloidosis research in the world. For more information, visit www.arci.org
Part 1 – Diagnosing Amyloidosis
Part 2 – Management of AL Amyloidosis
Part 3 – Management of ATTR Amyloidosis
Part 4 – Diving Deeper into Amyloidosis Management
Officially endorsed by the Heart Failure Society of America. The opinions presented in this educational activity do not necessarily reflect the opinions or recommendations of the HFSA.
This program is supported in part by educational grants from:
- Akcea Therapeutics
- Alnylam Pharmaceuticals
- Eidos Therapeutics, Inc.
- Pfizer Inc.
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.